OrbiMed’s Monte Rosa Therapeutics GLUE Stock Holding History

OrbiMed’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27,369	Closed	-$208K	–	133
2022 Q4	$208K	Sell	27,369 -90,086	-77%	-$750K	﹤0.01%	115
2022 Q3	$960	Buy	+117,455	New	+$1.08M	0.02%	127
2021 Q3	–	Sell	-350,000	Closed	-$7.95M	–	181
2021 Q2	$7.95M	Buy	+350,000	New	+$7.13M	0.08%	137

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed's GLUE Position: Q1 2023 in Review

OrbiMed sold out of Monte Rosa Therapeutics (GLUE) in Q1 2023, closing a stake of 27,369 shares — an estimated $208K sold.

OrbiMed first reported a position in GLUE in Q2 2021 and held it in 3 quarters. The position peaked at $7.95M in Q2 2021. 69 funds tracked by Wall St. Rank hold GLUE as of Q1 2023.

OrbiMed reported no remaining Monte Rosa Therapeutics position as of Q1 2023 after selling out during the quarter.
OrbiMed sold 27,369 Monte Rosa Therapeutics shares in Q1 2023, an estimated $208K.
OrbiMed first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 3 quarters.
OrbiMed's Monte Rosa Therapeutics position peaked at $7.95M in Q2 2021.
69 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2023.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.